Financial Data and Key Metrics Changes - Total company revenue for Q4 was $1.173 billion, reflecting a growth of 19% on a constant currency basis. For the full year, total revenue was $4.146 billion, showing a growth of 12% on a constant currency basis [36][67] - Adjusted EBITDA for Q4 was $231 million, representing a 28% growth compared to Q4 2022. Full year adjusted EBITDA was $738 million, negatively impacted by currency headwinds of $51 million [38][39] - Adjusted gross margin for Q4 was 62.5%, up 470 basis points compared to Q4 2022. For the full year, adjusted gross margin was 61%, up 130 basis points compared to last year [38] Business Line Data and Key Metrics Changes - Vision care revenue for Q4 was $662 million, increasing by 8% on a constant currency basis. For the full year, vision care revenue was $2.543 billion, up 10% on a constant currency basis [37] - Surgical segment revenue for Q4 was $204 million, a 7% increase on a constant currency basis. For the full year, growth was also 7% on a constant currency basis [29] - Pharma segment revenue for Q4 was $307 million, representing constant currency growth of 66%. For the full year, pharma revenue was $836 million, reflecting constant currency growth of 24% [65] Market Data and Key Metrics Changes - Daily silicone hydrogel (SiHy) lenses reported a revenue growth of 31% in Q4. The overall contact lens market is growing around 7% to 8% globally [10][56] - The premium intraocular lens (IOL) portfolio grew by 30% in constant currency in Q4, indicating strong demand in the surgical market [48] Company Strategy and Development Direction - The company is focused on driving margin expansion sustainably, with expectations for margin improvement in 2024, 2025, and 2026 [3][17] - Significant investments are being made in R&D capabilities and business development to build a robust pipeline across all business segments [9][43] - The company aims to optimize its supply chain to become a competitive advantage, with ongoing efforts to streamline operations and reduce complexity [70] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2024, highlighting a strong focus on execution and the potential for significant growth driven by recent and upcoming product launches [20][41] - The company is committed to investing in marketing and sales for Miebo and Xiidra to unlock their full potential in the dry eye market [41][67] Other Important Information - The company expects 2024 revenue guidance in the range of $4.6 billion to $4.7 billion, reflecting expected constant currency growth of approximately 12% to 14% [67] - Currency headwinds are anticipated to negatively impact revenue by approximately $40 million for the full year [67] Q&A Session Summary Question: What percentage of your contact lenses are silicone hydrogel today versus a year ago? - The company reported that silicone hydrogel lenses are currently around 10% of their portfolio, growing rapidly with double-digit growth [10] Question: How are you feeling about M&A at this stage? - Management indicated that the priority is to digest and delever the Novartis assets, while also exploring smaller products and R&D assets for future growth [9] Question: Can you provide insights on Xiidra's performance and future expectations? - Xiidra delivered $106 million in revenue in Q4, exceeding guidance. The company expects to generate approximately $400 million in revenue for Xiidra in 2024 [65][66] Question: What is the outlook for Miebo's contribution to growth? - Miebo is expected to contribute approximately $95 million in revenue in 2024, with strong early performance and positive feedback from eyecare professionals [67]

Bausch + Lomb (BLCO) reported $1.17 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 17.8%. EPS of $0.24 for the same period compares to $0.23 a year ago.The reported revenue represents a surprise of +7.50% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.17, the EPS surprise was +41.18%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...

Bausch + Lomb Corp.’s stock soared 10% early Wednesday, after the vision-care company’s adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024. The Vaughan, Ontario-based company BLCO, +1.96% had a net loss of $54 million, or 15 cents a share, for the quarter, after a loss of $1 million in the year-earlier period. Adjusted per-share earnings came to 24 cents, ahead of the 17-cent FactSet consensus.Revenue rose to $1.173 billion from $996 million a year ago, also ahe ...

9 1. Products with sales outside the United States impacted by F/X changes. 2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios. 3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the repo ...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance VAUGHAN, Ontario, Feb. 21, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full year 2023 financial results. Select Fourth-Quarter Company Highlights ___________________________________ 1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) ...

Analysts on Wall Street project that Bausch + Lomb (BLCO) will announce quarterly earnings of $0.17 per share in its forthcoming report, representing a decline of 26.1% year over year. Revenues are projected to reach $1.09 billion, increasing 9.6% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 18.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Bausch + Lomb (BLCO) . This company, which is in the Zacks Medical Services industry, shows potential for another earnings beat.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 17.36%, on average, in the last two quarters.For t ...

The market expects Bausch + Lomb (BLCO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 21, 2024, might help the stock move higher if these key number ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start ...